You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBepridil
Accession NumberDB01244  (APRD00727)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionA long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).
Structure
Thumb
Synonyms
Bepadin
Bepridil
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AngoprilNot Available
CordiumNot Available
VascorNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Bepridil hydrochloride
ThumbNot applicableDBSALT001436
Categories
UNII755BO701MA
CAS number64706-54-3
WeightAverage: 366.5396
Monoisotopic: 366.26711372
Chemical FormulaC24H34N2O
InChI KeyInChIKey=UIEATEWHFDRYRU-UHFFFAOYSA-N
InChI
InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3
IUPAC Name
N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline
SMILES
CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylmethylamines
Direct ParentPhenylmethylamines
Alternative Parents
Substituents
  • Dialkylarylamine
  • Phenylmethylamine
  • Benzylamine
  • Aralkylamine
  • Aniline
  • N-alkylpyrrolidine
  • Pyrrolidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of hypertension, and chronic stable angina (classic effort-associated angina).
PharmacodynamicsBepridil is a calcium channel blocker that has well characterized anti-anginal properties and known but poorly characterized type 1 anti-arrhythmic and anti-hypertensive properties. It is not related chemically to other calcium channel blockers such as diltiazem hydrochloride, nifedipine and verapamil hydrochloride.
Mechanism of actionBepridil has inhibitory effects on both the slow calcium (L-type) and fast sodium inward currents in myocardial and vascular smooth muscle, interferes with calcium binding to calmodulin, and blocks both voltage and receptor operated calcium channels. Bepridil inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. This has been demonstrated in isolated myocardial and vascular smooth muscle preparations in which both the slope of the calcium dose response curve and the maximum calcium-induced inotropic response were significantly reduced by bepridil. In cardiac myocytes in vitro, bepridil was shown to be tightly bound to actin. Bepridil regularly reduces heart rate and arterial pressure at rest and at a given level of exercise by dilating peripheral arterioles and reducing total peripheral resistance (afterload) against which the heart works.
Related Articles
AbsorptionRapidly and completely absorbed after oral administration.
Volume of distributionNot Available
Protein binding99%
Metabolism

Hepatic.

Route of eliminationNot Available
Half life24-50 hours
ClearanceNot Available
ToxicityThere has been one experience with overdosage in which a patient inadvertently took a single dose of 1600 mg of bepridil. The patient was observed for 72 hours in intensive care, but no significant adverse experiences were noted.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9859
Blood Brain Barrier+0.9003
Caco-2 permeable+0.5593
P-glycoprotein substrateSubstrate0.7013
P-glycoprotein inhibitor IInhibitor0.7951
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterInhibitor0.6774
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.5495
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.8462
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5636
Ames testNon AMES toxic0.67
CarcinogenicityNon-carcinogens0.8688
BiodegradationNot ready biodegradable0.9938
Rat acute toxicity2.4903 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.536
hERG inhibition (predictor II)Inhibitor0.796
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point128Mauvernay, R.Y., Busch, N., Moleyre, J., Monteil, A. and Simond, J.; U.S. Patent 3,962,238; June 8,1976; assigned to Centre Europeen de Recherches Mauvernay "CERM".
water solubilitySlightly solubleNot Available
logP5.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00655 mg/mLALOGPS
logP5.33ALOGPS
logP5.49ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)9.16ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area15.71 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity115.12 m3·mol-1ChemAxon
Polarizability43.5 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Mauvernay, R.Y., Busch, N., Moleyre, J., Monteil, A. and Simond, J.; U.S. Patent 3,962,238;
June 8,1976; assigned to Centre Europeen de Recherches Mauvernay “CERM”.

General ReferencesNot Available
External Links
ATC CodesC08EA02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Bepridil.
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Bepridil.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Bepridil.
AbirateroneThe metabolism of Bepridil can be decreased when combined with Abiraterone.
AcebutololAcebutolol may increase the hypotensive activities of Bepridil.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Bepridil.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Bepridil.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Bepridil.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Bepridil.
AlfuzosinAlfuzosin may increase the hypotensive activities of Bepridil.
AliskirenBepridil may increase the hypotensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Bepridil.
AlprenololAlprenolol may increase the hypotensive activities of Bepridil.
AmbrisentanBepridil may increase the hypotensive activities of Ambrisentan.
AmifostineBepridil may increase the hypotensive activities of Amifostine.
AmiodaroneThe metabolism of Bepridil can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Bepridil.
AmlodipineAmlodipine may increase the hypotensive activities of Bepridil.
AmobarbitalThe metabolism of Bepridil can be increased when combined with Amobarbital.
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Bepridil.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bepridil.
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Bepridil.
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Bepridil.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Bepridil.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Bepridil.
ArtemetherThe metabolism of Bepridil can be decreased when combined with Artemether.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Bepridil.
AtenololAtenolol may increase the hypotensive activities of Bepridil.
AtomoxetineThe metabolism of Bepridil can be decreased when combined with Atomoxetine.
AtosibanThe risk or severity of adverse effects can be increased when Bepridil is combined with Atosiban.
Atracurium besylateBepridil may increase the neuromuscular blocking activities of Atracurium besylate.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Bepridil.
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Bepridil.
BarbitalThe metabolism of Bepridil can be increased when combined with Barbital.
BenazeprilBenazepril may increase the hypotensive activities of Bepridil.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Bepridil.
BenmoxinBenmoxin may increase the hypotensive activities of Bepridil.
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Bepridil.
BethanidineBethanidine may increase the hypotensive activities of Bepridil.
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Bepridil.
BimatoprostBimatoprost may increase the hypotensive activities of Bepridil.
BisoprololBisoprolol may increase the hypotensive activities of Bepridil.
BoceprevirThe serum concentration of Bepridil can be increased when it is combined with Boceprevir.
BosentanBosentan may increase the hypotensive activities of Bepridil.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Bepridil.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Bepridil.
BretyliumBretylium may increase the hypotensive activities of Bepridil.
BrimonidineBepridil may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Bepridil.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Bepridil.
BupranololBepridil may increase the hypotensive activities of Bupranolol.
BupropionThe metabolism of Bepridil can be decreased when combined with Bupropion.
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Bepridil.
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Bepridil.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Bepridil.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Bepridil.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Bepridil.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Bepridil.
CandesartanCandesartan may increase the hypotensive activities of Bepridil.
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Bepridil.
CandoxatrilCandoxatril may increase the hypotensive activities of Bepridil.
CaptoprilCaptopril may increase the hypotensive activities of Bepridil.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Bepridil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Bepridil.
CaroxazoneCaroxazone may increase the hypotensive activities of Bepridil.
CarteololCarteolol may increase the hypotensive activities of Bepridil.
CarvedilolCarvedilol may increase the hypotensive activities of Bepridil.
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Bepridil.
CelecoxibThe metabolism of Bepridil can be decreased when combined with Celecoxib.
CeliprololBepridil may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Bepridil.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Bepridil.
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Bepridil.
ChloroquineThe metabolism of Bepridil can be decreased when combined with Chloroquine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Bepridil.
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Bepridil.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Bepridil.
ChlorpromazineThe metabolism of Bepridil can be decreased when combined with Chlorpromazine.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Bepridil.
CholecalciferolThe metabolism of Bepridil can be decreased when combined with Cholecalciferol.
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Bepridil.
CilazaprilBepridil may increase the hypotensive activities of Cilazapril.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Bepridil.
CimetidineThe metabolism of Bepridil can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Bepridil can be decreased when combined with Cinacalcet.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Bepridil.
CisaprideCisapride may increase the QTc-prolonging activities of Bepridil.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Bepridil.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Bepridil.
CitalopramThe metabolism of Bepridil can be decreased when combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Bepridil.
ClemastineThe metabolism of Bepridil can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Bepridil.
ClobazamThe metabolism of Bepridil can be decreased when combined with Clobazam.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Bepridil.
ClomipramineThe metabolism of Bepridil can be decreased when combined with Clomipramine.
ClonidineClonidine may increase the hypotensive activities of Bepridil.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Bepridil.
ClotrimazoleThe metabolism of Bepridil can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Bepridil.
ClozapineThe metabolism of Bepridil can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Bepridil can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Bepridil.
CocaineThe metabolism of Bepridil can be decreased when combined with Cocaine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Bepridil.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Bepridil.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Bepridil.
CryptenamineCryptenamine may increase the hypotensive activities of Bepridil.
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bepridil.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Bepridil.
CyclothiazideCyclothiazide may increase the hypotensive activities of Bepridil.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Bepridil.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Bepridil.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Bepridil.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Bepridil.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Bepridil.
DarifenacinThe metabolism of Bepridil can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Bepridil can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Bepridil.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Bepridil.
DebrisoquinBepridil may increase the hypotensive activities of Debrisoquin.
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Bepridil.
DelavirdineThe metabolism of Bepridil can be decreased when combined with Delavirdine.
DeserpidineBepridil may increase the hypotensive activities of Deserpidine.
DesipramineThe metabolism of Bepridil can be decreased when combined with Desipramine.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Bepridil.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Bepridil.
DiazoxideDiazoxide may increase the hypotensive activities of Bepridil.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Bepridil.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Bepridil.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Bepridil.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Bepridil.
DiltiazemDiltiazem may increase the hypotensive activities of Bepridil.
DiphenhydramineThe metabolism of Bepridil can be decreased when combined with Diphenhydramine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Bepridil.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Bepridil.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Bepridil.
DorzolamideDorzolamide may increase the hypotensive activities of Bepridil.
DoxazosinDoxazosin may increase the hypotensive activities of Bepridil.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Bepridil.
DronedaroneThe metabolism of Bepridil can be decreased when combined with Dronedarone.
DuloxetineThe metabolism of Bepridil can be decreased when combined with Duloxetine.
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Bepridil.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Bepridil.
EfavirenzThe serum concentration of Bepridil can be decreased when it is combined with Efavirenz.
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Bepridil.
EfonidipineBepridil may increase the hypotensive activities of Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Bepridil.
EliglustatThe metabolism of Bepridil can be decreased when combined with Eliglustat.
EnalaprilEnalapril may increase the hypotensive activities of Bepridil.
EnalaprilatBepridil may increase the hypotensive activities of Enalaprilat.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Bepridil.
EpoprostenolEpoprostenol may increase the hypotensive activities of Bepridil.
EprosartanEprosartan may increase the hypotensive activities of Bepridil.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Bepridil.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Bepridil.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Bepridil.
EstriolThe serum concentration of Estriol can be increased when it is combined with Bepridil.
EstroneThe serum concentration of Estrone can be increased when it is combined with Bepridil.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Bepridil.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Bepridil.
EtravirineThe serum concentration of Bepridil can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Bepridil.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Bepridil.
FelodipineFelodipine may increase the hypotensive activities of Bepridil.
FenoldopamFenoldopam may increase the hypotensive activities of Bepridil.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Bepridil.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Bepridil.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Bepridil.
FluconazoleThe serum concentration of Bepridil can be increased when it is combined with Fluconazole.
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Bepridil.
FluoxetineThe metabolism of Bepridil can be decreased when combined with Fluoxetine.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Bepridil.
FluvoxamineThe metabolism of Bepridil can be decreased when combined with Fluvoxamine.
FosinoprilFosinopril may increase the hypotensive activities of Bepridil.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Bepridil.
FurazolidoneFurazolidone may increase the hypotensive activities of Bepridil.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Bepridil.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Bepridil.
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Bepridil.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Bepridil.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Bepridil.
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Bepridil.
GuanabenzGuanabenz may increase the hypotensive activities of Bepridil.
GuanadrelGuanadrel may increase the hypotensive activities of Bepridil.
GuanethidineGuanethidine may increase the hypotensive activities of Bepridil.
GuanfacineGuanfacine may increase the hypotensive activities of Bepridil.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Bepridil.
HaloperidolThe metabolism of Bepridil can be decreased when combined with Haloperidol.
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Bepridil.
HexamethoniumBepridil may increase the hypotensive activities of Hexamethonium.
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Bepridil.
HexobarbitalThe metabolism of Bepridil can be increased when combined with Hexobarbital.
HydracarbazineHydracarbazine may increase the hypotensive activities of Bepridil.
HydralazineBepridil may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Bepridil.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Bepridil.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Bepridil.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Bepridil.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Bepridil.
IloprostIloprost may increase the hypotensive activities of Bepridil.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Bepridil.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Bepridil.
ImipramineThe metabolism of Bepridil can be decreased when combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Bepridil.
IndapamideIndapamide may increase the hypotensive activities of Bepridil.
IndenololBepridil may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Bepridil.
IndinavirThe metabolism of Bepridil can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Bepridil.
IndoraminBepridil may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Bepridil.
IproniazidIproniazid may increase the hypotensive activities of Bepridil.
IrbesartanIrbesartan may increase the hypotensive activities of Bepridil.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Bepridil.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bepridil.
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Bepridil.
IsoniazidThe metabolism of Bepridil can be decreased when combined with Isoniazid.
IsradipineIsradipine may increase the hypotensive activities of Bepridil.
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Bepridil.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Bepridil.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Bepridil.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Bepridil.
KetoconazoleThe metabolism of Bepridil can be decreased when combined with Ketoconazole.
LabetalolLabetalol may increase the hypotensive activities of Bepridil.
LacidipineBepridil may increase the hypotensive activities of Lacidipine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Bepridil.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Bepridil.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Bepridil.
LatanoprostLatanoprost may increase the hypotensive activities of Bepridil.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Bepridil.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Bepridil.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Bepridil.
LercanidipineLercanidipine may increase the hypotensive activities of Bepridil.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Bepridil.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Bepridil.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Bepridil.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Bepridil.
LisinoprilLisinopril may increase the hypotensive activities of Bepridil.
LofexidineBepridil may increase the hypotensive activities of Lofexidine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Bepridil.
LopinavirThe metabolism of Bepridil can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Bepridil can be decreased when combined with Lorcaserin.
LosartanLosartan may increase the hypotensive activities of Bepridil.
LumefantrineThe metabolism of Bepridil can be decreased when combined with Lumefantrine.
MacitentanBepridil may increase the hypotensive activities of Macitentan.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium hydroxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium salicylate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium Sulfate.
ManidipineBepridil may increase the hypotensive activities of Manidipine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Bepridil.
MebanazineMebanazine may increase the hypotensive activities of Bepridil.
MecamylamineMecamylamine may increase the hypotensive activities of Bepridil.
MethadoneThe metabolism of Bepridil can be decreased when combined with Methadone.
MethohexitalThe metabolism of Bepridil can be increased when combined with Methohexital.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Bepridil.
MethotrimeprazineThe metabolism of Bepridil can be decreased when combined with Methotrimeprazine.
MethyldopaMethyldopa may increase the hypotensive activities of Bepridil.
Methylene blueMethylene blue may increase the hypotensive activities of Bepridil.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bepridil.
MethylphenobarbitalThe metabolism of Bepridil can be increased when combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Bepridil.
MetipranololMetipranolol may increase the hypotensive activities of Bepridil.
MetolazoneMetolazone may increase the hypotensive activities of Bepridil.
MetoprololMetoprolol may increase the hypotensive activities of Bepridil.
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Bepridil.
MibefradilBepridil may increase the hypotensive activities of Mibefradil.
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Bepridil.
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Bepridil.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Bepridil.
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Bepridil.
MinaprineMinaprine may increase the hypotensive activities of Bepridil.
MinoxidilMinoxidil may increase the hypotensive activities of Bepridil.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Bepridil.
MirabegronThe metabolism of Bepridil can be decreased when combined with Mirabegron.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Bepridil.
MivacuriumBepridil may increase the neuromuscular blocking activities of Mivacurium.
MoclobemideMoclobemide may increase the hypotensive activities of Bepridil.
MoexiprilMoexipril may increase the hypotensive activities of Bepridil.
MolsidomineMolsidomine may increase the hypotensive activities of Bepridil.
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Bepridil.
MorphineThe serum concentration of Morphine can be increased when it is combined with Bepridil.
MoxonidineBepridil may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Bepridil.
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Bepridil.
NadololNadolol may increase the hypotensive activities of Bepridil.
NafcillinThe metabolism of Bepridil can be increased when combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Bepridil.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Bepridil.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Bepridil.
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Bepridil.
NebivololBepridil may increase the hypotensive activities of Nebivolol.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Bepridil.
NevirapineThe metabolism of Bepridil can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Bepridil.
NicardipineNicardipine may increase the hypotensive activities of Bepridil.
NicorandilBepridil may increase the hypotensive activities of Nicorandil.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Bepridil.
NiguldipineBepridil may increase the hypotensive activities of Niguldipine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Bepridil.
NilotinibThe metabolism of Bepridil can be decreased when combined with Nilotinib.
NilvadipineBepridil may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Bepridil.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Bepridil.
NisoldipineNisoldipine may increase the hypotensive activities of Bepridil.
NitrendipineNitrendipine may increase the hypotensive activities of Bepridil.
NitroprussideBepridil may increase the hypotensive activities of Nitroprusside.
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Bepridil.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Bepridil.
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Bepridil.
ObinutuzumabBepridil may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Bepridil.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Bepridil.
OlmesartanOlmesartan may increase the hypotensive activities of Bepridil.
OmapatrilatOmapatrilat may increase the hypotensive activities of Bepridil.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Bepridil.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Bepridil.
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Bepridil.
OxprenololBepridil may increase the hypotensive activities of Oxprenolol.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Bepridil.
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Bepridil.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Bepridil.
PanobinostatThe metabolism of Bepridil can be decreased when combined with Panobinostat.
PargylineBepridil may increase the hypotensive activities of Pargyline.
ParoxetineThe metabolism of Bepridil can be decreased when combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Bepridil.
Peginterferon alfa-2bThe serum concentration of Bepridil can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololBepridil may increase the hypotensive activities of Penbutolol.
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Bepridil.
PentobarbitalThe metabolism of Bepridil can be increased when combined with Pentobarbital.
PentoliniumPentolinium may increase the hypotensive activities of Bepridil.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bepridil.
PerindoprilPerindopril may increase the hypotensive activities of Bepridil.
PhenelzinePhenelzine may increase the hypotensive activities of Bepridil.
PheniprazinePheniprazine may increase the hypotensive activities of Bepridil.
PhenobarbitalThe metabolism of Bepridil can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Bepridil.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Bepridil.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bepridil.
PhentolaminePhentolamine may increase the hypotensive activities of Bepridil.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Bepridil.
PinacidilBepridil may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Bepridil.
PirlindolePirlindole may increase the hypotensive activities of Bepridil.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Bepridil.
PivhydrazinePivhydrazine may increase the hypotensive activities of Bepridil.
PolythiazideBepridil may increase the hypotensive activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Bepridil.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Bepridil.
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Bepridil.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Bepridil.
PrazosinPrazosin may increase the hypotensive activities of Bepridil.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Bepridil.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Bepridil.
PrimidoneThe metabolism of Bepridil can be increased when combined with Primidone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Bepridil.
PromazineThe metabolism of Bepridil can be decreased when combined with Promazine.
PropranololPropranolol may increase the hypotensive activities of Bepridil.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Bepridil.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Bepridil.
QuinaprilQuinapril may increase the hypotensive activities of Bepridil.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Bepridil.
QuinidineThe metabolism of Bepridil can be decreased when combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Bepridil.
QuinineThe serum concentration of Quinine can be increased when it is combined with Bepridil.
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Bepridil.
RamiprilRamipril may increase the hypotensive activities of Bepridil.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Bepridil.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Bepridil.
RanolazineThe metabolism of Bepridil can be decreased when combined with Ranolazine.
RapacuroniumBepridil may increase the neuromuscular blocking activities of Rapacuronium.
RasagilineRasagiline may increase the hypotensive activities of Bepridil.
RemikirenRemikiren may increase the hypotensive activities of Bepridil.
RescinnamineBepridil may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Bepridil.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Bepridil.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Bepridil.
RiociguatBepridil may increase the hypotensive activities of Riociguat.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Bepridil.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Bepridil.
RitonavirThe metabolism of Bepridil can be decreased when combined with Ritonavir.
RituximabBepridil may increase the hypotensive activities of Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Bepridil.
RolapitantThe metabolism of Bepridil can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Bepridil.
RopiniroleThe metabolism of Bepridil can be decreased when combined with Ropinirole.
SafrazineSafrazine may increase the hypotensive activities of Bepridil.
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Bepridil.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Bepridil.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Bepridil.
SaprisartanBepridil may increase the hypotensive activities of Saprisartan.
SaquinavirBepridil may increase the arrhythmogenic activities of Saquinavir.
SecobarbitalThe metabolism of Bepridil can be increased when combined with Secobarbital.
SelegilineSelegiline may increase the hypotensive activities of Bepridil.
SelexipagBepridil may increase the hypotensive activities of Selexipag.
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Bepridil.
SertralineThe metabolism of Bepridil can be decreased when combined with Sertraline.
SildenafilSildenafil may increase the antihypertensive activities of Bepridil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Bepridil.
SilodosinSilodosin may increase the hypotensive activities of Bepridil.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Bepridil.
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Bepridil.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Bepridil.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Bepridil.
SitaxentanBepridil may increase the hypotensive activities of Sitaxentan.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Bepridil.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Bepridil.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Bepridil.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Bepridil.
SpiraprilBepridil may increase the hypotensive activities of Spirapril.
StiripentolThe metabolism of Bepridil can be decreased when combined with Stiripentol.
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Bepridil.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Bepridil.
TadalafilTadalafil may increase the antihypertensive activities of Bepridil.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Bepridil.
TamsulosinTamsulosin may increase the hypotensive activities of Bepridil.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Bepridil.
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Bepridil.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Bepridil.
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Bepridil.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Bepridil.
TelmisartanTelmisartan may increase the hypotensive activities of Bepridil.
TemocaprilBepridil may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Bepridil.
TerazosinTerazosin may increase the hypotensive activities of Bepridil.
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Bepridil.
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Bepridil.
TerlipressinBepridil may increase the hypotensive activities of Terlipressin.
ThiamylalThe metabolism of Bepridil can be increased when combined with Thiamylal.
ThiopentalThe metabolism of Bepridil can be increased when combined with Thiopental.
ThioridazineThe metabolism of Bepridil can be decreased when combined with Thioridazine.
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Bepridil.
TiboloneBepridil may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Bepridil.
TiclopidineThe metabolism of Bepridil can be decreased when combined with Ticlopidine.
TicrynafenBepridil may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Bepridil.
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Bepridil.
TipranavirThe serum concentration of Bepridil can be increased when it is combined with Tipranavir.
TolazolineTolazoline may increase the hypotensive activities of Bepridil.
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Bepridil.
ToloxatoneToloxatone may increase the hypotensive activities of Bepridil.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Bepridil.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Bepridil.
TorasemideTorasemide may increase the hypotensive activities of Bepridil.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Bepridil.
TrandolaprilTrandolapril may increase the hypotensive activities of Bepridil.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bepridil.
TranylcypromineTranylcypromine may increase the hypotensive activities of Bepridil.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Bepridil.
TravoprostTravoprost may increase the hypotensive activities of Bepridil.
TreprostinilTreprostinil may increase the hypotensive activities of Bepridil.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Bepridil.
TrimazosinBepridil may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Bepridil.
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Bepridil.
UdenafilUdenafil may increase the antihypertensive activities of Bepridil.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Bepridil.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Bepridil.
UnoprostoneBepridil may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Bepridil.
VardenafilVardenafil may increase the antihypertensive activities of Bepridil.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Bepridil.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Bepridil.
VenlafaxineThe metabolism of Bepridil can be decreased when combined with Venlafaxine.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Bepridil.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Bepridil.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Bepridil.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Bepridil.
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Bepridil.
XylometazolineBepridil may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Bepridil.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Bepridil.
ZiprasidoneThe metabolism of Bepridil can be decreased when combined with Ziprasidone.
Food Interactions
  • Alcohol may further decrease blood pressure and increase dizziness and drowsiness
  • Take with food to reduce nausea.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1A gives rise to P and/or Q-type calcium currents. P/Q-type calcium channels belong to...
Gene Name:
CACNA1A
Uniprot ID:
O00555
Molecular Weight:
282362.39 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Bezprozvanny I, Tsien RW: Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 1995 Sep;48(3):540-9. [PubMed:7565636 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1H gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1H
Uniprot ID:
O95180
Molecular Weight:
259160.2 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221 ]
  2. Bezprozvanny I, Tsien RW: Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 1995 Sep;48(3):540-9. [PubMed:7565636 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) and possibly T-type (CACNA1G). Overexpression induces apoptosis.
Gene Name:
CACNA2D2
Uniprot ID:
Q9NY47
Molecular Weight:
129816.095 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221 ]
  2. Bezprozvanny I, Tsien RW: Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 1995 Sep;48(3):540-9. [PubMed:7565636 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Molecular Weight:
112895.01 Da
References
  1. Kovacic H, Gallice P, Crevat A: Inhibition of sodium pump by bepridil. An in vitro and microcalorimetric study. Biochem Pharmacol. 1992 Oct 20;44(8):1529-34. [PubMed:1329768 ]
  2. Raess BU, Record DM: Inhibition of erythrocyte Ca2(+)-pump by Ca2+ antagonists. Biochem Pharmacol. 1990 Dec 1;40(11):2549-55. [PubMed:2148481 ]
  3. Smith SJ, England PJ: The effects of reported Ca2+ sensitisers on the rates of Ca2+ release from cardiac troponin C and the troponin-tropomyosin complex. Br J Pharmacol. 1990 Aug;100(4):779-85. [PubMed:2207500 ]
  4. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041 ]
  5. Fuchs J, Mainka L, Reifart N, Zimmer G: Effects of bepridil on heart mitochondrial membrane and the isolated rat heart preparation. Arzneimittelforschung. 1986 Feb;36(2):209-12. [PubMed:2938592 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Potassium channel that plays an important role in a number of tissues, including heart, inner ear, stomach and colon (By similarity) (PubMed:10646604). Associates with KCNE beta subunits that modulates current kinetics (By similarity) (PubMed:9312006, PubMed:9108097, PubMed:8900283, PubMed:10646604, PubMed:11101505, PubMed:19687231). Induces a voltage-dependent by rapidly activating and slowly ...
Gene Name:
KCNQ1
Uniprot ID:
P51787
Molecular Weight:
74697.925 Da
References
  1. Chouabe C, Drici MD, Romey G, Barhanin J: Effects of calcium channel blockers on cloned cardiac K+ channels IKr and IKs. Therapie. 2000 Jan-Feb;55(1):195-202. [PubMed:10860024 ]
  2. Yumoto Y, Horie M, Kubota T, Ninomiya T, Kobori A, Takenaka K, Takano M, Niwano S, Izumi T: Bepridil block of recombinant human cardiac IKs current shows a time-dependent unblock. J Cardiovasc Pharmacol. 2004 Feb;43(2):178-82. [PubMed:14716203 ]
  3. Chouabe C, Drici MD, Romey G, Barhanin J, Lazdunski M: HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol. 1998 Oct;54(4):695-703. [PubMed:9765513 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Troponin t binding
Specific Function:
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site for tropomyosin and Tn-C. The binding of calcium to Tn-C abolishes the inhibitory action of Tn on actin filaments.
Gene Name:
TNNC1
Uniprot ID:
P63316
Molecular Weight:
18402.36 Da
References
  1. Abusamhadneh E, Abbott MB, Dvoretsky A, Finley N, Sasi S, Rosevear PR: Interaction of bepridil with the cardiac troponin C/troponin I complex. FEBS Lett. 2001 Sep 28;506(1):51-4. [PubMed:11591369 ]
  2. Wang X, Li MX, Sykes BD: Structure of the regulatory N-domain of human cardiac troponin C in complex with human cardiac troponin I147-163 and bepridil. J Biol Chem. 2002 Aug 23;277(34):31124-33. Epub 2002 Jun 11. [PubMed:12060657 ]
  3. MacLachlan LK, Reid DG, Mitchell RC, Salter CJ, Smith SJ: Binding of a calcium sensitizer, bepridil, to cardiac troponin C. A fluorescence stopped-flow kinetic, circular dichroism, and proton nuclear magnetic resonance study. J Biol Chem. 1990 Jun 15;265(17):9764-70. [PubMed:2351672 ]
  4. Kleerekoper Q, Liu W, Choi D, Putkey JA: Identification of binding sites for bepridil and trifluoperazine on cardiac troponin C. J Biol Chem. 1998 Apr 3;273(14):8153-60. [PubMed:9525919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041 ]
  2. Lamers JM, Verdouw PD, Mas-Oliva J: The effects of felodipine and bepridil on calcium-stimulated calmodulin binding and calcium pumping ATPase of cardiac sarcolemma before and after removal of endogenous calmodulin. Mol Cell Biochem. 1987 Dec;78(2):169-76. [PubMed:2964559 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a preference for cGMP as a substrate.
Gene Name:
PDE1B
Uniprot ID:
Q01064
Molecular Weight:
61379.235 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a higher affinity for cGMP than for cAMP.
Gene Name:
PDE1A
Uniprot ID:
P54750
Molecular Weight:
61251.38 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23